CfPA-The Center for Professional Advancement, Amsterdam, The Netherlands
8-10 May 2019
Who Should Attend?
This is an in depth course intended for product development scientists and technologists and support groups concerned with the development, designing and processing of tablets and similar oral products.
The material will be presented in such a way as to be of value to a varying level of expertise. This course will especially benefit those in:
• Formulation Development
• Quality Assurance
• Research and Development
• Regulatory Affairs
• Engineering Support
Note: Persons seeking a broader based program may wish to consider an alternative, more generalized course offered by CfPA in this area of technology.
| Dr. Cecil W. Propst, Managing Director, Propst Consulting Services|
Dr. Cecil W. Propst is Managing Director at Propst Consulting Services, a formulation, and engineering support LLC located in Norton Shores MI. He was Director of R&D (Grand Haven site) at SPI Pharma until 2015. He served as Director of Quality Assurance and Technical Services at Fleming and Company, and before that, President of Manufacturing Chemists. His duties included system design, product and process development and regulatory affairs. Previously, he served as cGMP Facilities Director for the University of Maryland at Baltimore, in connection with the University’s SUPAC contract with the FDA. Dr. Propst also served as Director of Technical Development for Stellar Manufacturing; Director of Quality Compliance for SmithKline Beecham; Director, Quality Assurance for Norcliff Thayer (a Revlon Company); and Group Leader/Product Development and Manager/Quality Control for Lewis Howe Company. He serves as a consultant in the area of product development and process investigations for the chemical, diagnostic, food, engineering and beverage industries.
|Dr. John K. Tillotson, Technical Manager, Abitec Inc.|
Dr. John Tillotson, Technical Manager, Abitec Inc., received his B.S. in Pharmacy from Ferris State University and his Ph.D. in Industrial Pharmacy from the University of Cincinnati.
Dr. Tillotson’s primary areas of interest are quick dissolve tablet technologies, directly compressible modalities and multiple-regression analysis. He was involved with the development and optimization of bumetanide sustained release technologies has several quick dissolve systems for nutraceuticals, OTC, and prescription products. Dr. Tillotson has presented at various workshops, invited symposiums, and/or poster presentations at national and international meetings. His published papers discuss the use of multiple-response optimization and the benefits of various ODT excipient systems. He is a member of the Rho Chi Pharmaceutical Honor Society and of the American Association of Pharmaceutical Scientists.